Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase NA 1Phase 1/2 1Phase 1 1

Status

Completed 2Unknown 1

Sponsor Class

OTHER_GOV 1OTHER 1INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gynecologic 2Genitourinary 1

Conditions

Breast Neoplasms 2760Carcinoma, Non-Small-Cell Lung 2260Prostatic Neoplasms 1425Colorectal Neoplasms 1290Neoplasms 1258Multiple Myeloma 1084Lung Neoplasms 1048Neoplasm Metastasis 994Leukemia, Myeloid, Acute 984Lymphoma 900Melanoma 862Pancreatic Neoplasms 818Ovarian Neoplasms 805Carcinoma, Hepatocellular 782Stomach Neoplasms 753Recurrence 750Leukemia 733Lymphoma, Non-Hodgkin 684Leukemia, Lymphocytic, Chronic, B-Cell 665Lymphoma, Large B-Cell, Diffuse 616Squamous Cell Carcinoma of Head and Neck 615Precursor Cell Lymphoblastic Leukemia-Lymphoma 605Head and Neck Neoplasms 596Brain Neoplasms 592Carcinoma, Renal Cell 586Glioblastoma 572Rectal Neoplasms 563Myelodysplastic Syndromes 522Sarcoma 521Lymphoma, Follicular 516

Interventions

niraparib 1avelumab 1Ocoxin 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Gonadal Disorders × Clear all
NCT03562897 2022-07-06

Evaluation of Ocoxin-Viusid® in Advanced or Metastatic Ovarian Epithelial Cancer

Catalysis SL

Phase 2 Completed
40 enrolled
Gynecologic

Adnexal Diseases, Carcinoma, Endocrine System Diseases, Endocrine Gland Neoplasms, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Female, Genital Neoplasms, Female, Gonadal Disorders, Neoplasm Metastasis, Neoplasms, Glandular and Epithelial, Ovarian Diseases, Ovarian Neoplasms, Urogenital Neoplasms, Female Urogenital Diseases

NCT04556071 2020-11-10

AVANIRA3

Jiangsu Cancer Institute & Hospital

Phase 2 Unknown
32 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial, Adnexal Diseases, Carcinoma, Endocrine System Diseases, Endocrine Gland Neoplasms, Fallopian Tube Neoplasms, Genital Diseases, Female, Genital Neoplasms, Female, Gonadal Disorders, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Glandular and Epithelial, Ovarian Diseases, Ovarian Neoplasms, Urogenital Neoplasms

NCT03403777 2019-03-05

Avelumab in Refractory Testicular Germ Cell Cancer.

National Cancer Institute, Slovakia

Phase 2 Completed
8 enrolled
Genitourinary

Gonadal Disorders, Neoplasms, Neoplasms, Germ Cell and Embryonal, Testicular Diseases, Testicular Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡